Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA-Reference-Cited by-同舟云学术

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA

Published:2018-01-29 Issue:7 Volume:47 Page:1023-1031
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chhatwal J.¹²³^ORCID,Chen Q.¹²,Ayer T.⁴,Bethea E. D.¹²³,Kanwal F.⁵⁶,Kowdley K. V.⁷,Wang X.⁸,Roberts M. S.⁹,Gordon S. C.¹⁰

Affiliation:

1. Massachusetts General Hospital Institute for Technology Assessment; Boston MA USA

2. Harvard Medical School; Boston MA USA

3. Liver Center and Gastrointestinal Division; Massachusetts General Hospital; Boston MA USA

4. H. Milton Stewart School of Industrial and Systems Engineering; Georgia Institute of Technology; Atlanta GA USA

5. Houston Veterans Affairs Health Services Research and Development Center of Excellence; Michael E. DeBakey Veterans Affairs Medical Center; Houston TX USA

6. Department of Medicine, Gastroenterology and Hepatology; Baylor College of Medicine; Houston TX USA

7. Swedish Medical Center; Seattle WA USA

8. Department of Industrial and Systems Engineering; University of Florida; Gainesville FL USA

9. Department of Health Policy and Management; University of Pittsburgh; Pittsburgh PA USA

10. Henry Ford Transplant Institute; Henry Ford Hospital; Detroit MI USA

Funder

National Center for Advancing Translational Sciences of the National Institutes of Health

Gilead Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14527/fullpdf

Reference31 articles.

1. Chronic hepatitis C infection;Rosen;N Engl J Med,2011

2. Dieterich D Bacon B Flamm S Final evaluation of HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population Vienna, Austria

3. AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org

4. Japsen B As pricey hepatitis pill Harvoni Joins Sovaldi, states erect medicaid hurdles. Forbes 2014 http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/

5. The changing burden of hepatitis C in the United States: model-based predictions;Kabiri;Ann Int Med,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatocellular carcinoma in hepatitis C virus patients treated with direct acting antivirals (DAAs) and patients not exposed to DAAs: a large center comparative study;Egyptian Journal of Radiology and Nuclear Medicine;2024-05-03

2. Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review;World Journal of Gastrointestinal Oncology;2024-04-15

3. Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study;The Korean Journal of Internal Medicine;2023-05-01

4. Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection;International Journal of Environmental Research and Public Health;2022-03-31

5. Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis;Hepatology;2022-02-03